Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org comes to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.

Podcast: Jennifer Miller, PhD & the Good Pharma Scorecard

Jennifer-Miller-2015I heard Jennifer Miller, PhD, use four numbers to discuss growing distrust of the drug industry: 12…70…1…17.

  • 12% of general public trust drug companies for being honest and ethical
  • 70% think they put profits before people
  • #1 is how the drug industry used to be ranked around the world – as the most admired industry…
  • …as recently as 17 years ago.

Miller is President of Bioethics International and an Assistant Professor at NYU School of Medicine. Here is her online bio.

Good Pharma ScorecardShe was one of 3 authors of a recent paper in BMJ Open that described a Good Pharma Scorecard to initially rank new drugs and their manufacturers on the transparency of clinical trial information for those new drugs. Of the limited sample analyzed, drugmakers Gilead Sciences and Sanofi rated poorly for having a large percentage of trials that were submitted to the FDA but never made public. GlaxoSmithKline, Pfizer and Johnson & Johnson got better grades.

As Dr. Joseph Ross, one of Miller’s co-authors, told the Washington Post:

“To me the right number is 100 percent; if you’re selling a product on the U.S. market, the public and the clinical science community has a right to be able to review the results.”

We interviewed Miller at the Stanford METRICS conference, “Improving Biomedical Research 2015.” Here is the third of three podcasts coming out of that conference (the others were with John Ioannidis and Brian Nosek):

News coverage of the Good Pharma Scorecard:

How Pharma Keeps a Trove of Drug Trials Out of Public View
The Washington Post Wonkblog

Drugmakers Kept One-Third of Trial Results Secret, Study Finds
Bloomberg News

Study Finds Big Pharma Skirts Laws, Ethical Standards in Keeping Trial Data Secret
Boston Business Journal

Gilead, Sanofi Would Tank in Bioethics International’s New Good Pharma Scorecard
MedCity News

Gilead, Sanofi Singled Out As Worst Offenders In Failing To Disclose Trial Data
FierceBiotech

Pharmaceutical Scorecard Shames Giants Over Research Cover-ups
The Australian


Disclosure: Miller’s work has received a grant from the Laura and John Arnold Foundation, which also supports HealthNewsReview.org

And thanks to The National Institute for Health Care Management Foundation for providing us with a grant to produce these podcasts.

Credit: podcast editor Cristeta Boarini

iTunes ratings & reviewsPlease note: if you have listened to any of our podcasts and like what you’ve heard, we’d appreciate it if you’d leave a Review and a Rating on the iTunes webpage where our podcasts can be found: https://itun.es/i6S86Qw. (You need to click on the “View in iTunes” button on the left of that page, then find the Ratings and Reviews tab.)

You can now subscribe to our podcasts on that iTunes page or via this RSS feed: http://feeds.soundcloud.com/users/soundcloud:users:167780656/sounds.rss

All episodes of our podcasts are archived on this page.

Comments

We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.

We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.